Dr. Dombkowski to Lead 23andMe’s Global Translational Collaborations
MOUNTAIN VIEW, CA–(Marketwire – Jul 5, 2011) –
Today 23andMe, an industry leader in personal genetics, announced the appointment of Ashley Ledbetter Dombkowski, PhD as Chief Business Officer. Dr. Dombkowski will assume global responsibility for 23andMe’s translational collaboration initiatives and will join the company’s executive leadership team reporting directly to 23andMe CEO and Co-Founder Anne Wojcicki. Dr. Dombkowski had previously been a member of 23andMe’s Board of Directors.
“Ashley’s remarkable ability to bring strategic vision to cutting edge technologies has resulted in increased levels of innovation, productivity and success for health care companies,” said Wojcicki. “We are confident her extensive experience working with physicians, academic researchers, patient-advocacy groups and entrepreneurs will complement the world-class expertise 23andMe has assembled in genetics, medicine, information technology, ancestry, privacy and consumer-focused fields. Ashley shares 23andMe’s goal of empowering individuals with their own genetic information and working to facilitate and accelerate research on their behalf. I’m delighted to welcome her to the company in this new, fully-dedicated role.”
“23andMe has pioneered a compelling approach to genetics by allowing individuals to learn from and interact with their own DNA while also contributing to research that could improve their lives,” said Dombkowski. “As a result of the company’s web-based research and rapidly growing database, the platform has already demonstrated unprecedented research utility. My aim is to ensure that discoveries made by, and on behalf of, our community can be translated so that users are not only participating in research, but benefiting from it.”
Dombkowski joins 23andMe after eleven years at MPM Capital where she served as Managing Director and a member of the firm’s Investment Committee. Prior to MPM she was a Health Care Analyst at Tiger Management and Dresdner RCM Global Investors. Dr. Dombkowski holds a Ph.D. in Mathematics from Rice University and a B.A. in Mathematics from Wellesley College.
23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. The company was named by TIME as a “Genius Company” in 2018, and featured as Fast Company's #2 Most Innovative Health Company in 2018. 23andMe has millions of customers worldwide, with more than 80 percent of customers consented to participate in research. 23andMe, Inc. is located in Sunnyvale, CA. More information is available at www.23andMe.com.